Skip to main content
Premium Trial:

Request an Annual Quote

Myriad and Abbott Extend Pharmacogenetics Pact

NEW YORK, Nov. 22 (GenomeWeb News) - Myriad Genetics and Abbott have extended a pharmacogenetics collaboration begun early last year, Myriad said today.


The collaboration will focus on identifying human genetic variation around drug targets in various stages of development, Myriad said.


Abbott will fund the research, and Myriad will use its sequencing technology and mutation screening software to analyze samples from various populations to identify genetic polymorphisms.


Financial details were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.